Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04510298 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia
A Phase 1 study, sponsored by Sirtsei Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT04510298 is a Phase 1 study that has completed, run by Sirtsei Pharmaceuticals. The registered enrollment target is 27 participants.
The verdict
NCT04510298, a Phase 1 study, has completed, sponsored by Sirtsei Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is a Phase 1B clinical study evaluating the safety and exploring the effectiveness of SP-624 as compared to placebo in the treatment of adults with schizophrenia experiencing acute psychosis.
Interventions
- DRUG Placebo
- DRUG SP-624
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2021-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04510298
The ClinicalTrials.gov registry entry for NCT04510298 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sirtsei Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04510298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04510298 about?
NCT04510298 is a clinical study titled "A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia". This is a Phase 1B clinical study evaluating the safety and exploring the effectiveness of SP-624 as compared to placebo in the treatment of adults with schizophrenia experiencing acute psychosis.
What is the current status of trial NCT04510298?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2020-10-15. Estimated completion is 2021-04-15.
What interventions are being tested in trial NCT04510298?
The interventions under investigation include: Placebo (DRUG), SP-624 (DRUG).
Who is sponsoring clinical trial NCT04510298?
This trial is sponsored by Sirtsei Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.